Advanced Therapy Medicinal Products Market Players:
- Novartis AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Takeda Pharmaceutical Company Limited
- Gilead Sciences, Inc.
- Bluebird Bio, Inc.
- BioMarin Pharmaceuticals Inc.
- Vericel Corporation
- Mallinckrodt Pharmaceuticals
- UniQure N.V.
- JCR Pharmaceuticals Co., Ltd.
- Spark Therapeutics, Inc.
- Kolon TissueGene,Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of advanced therapy medicinal products is assessed at USD 51.1 billion.
The global advanced therapy medicinal products market size was valued at over USD 45.2 billion in 2025 and is expected to expand at a CAGR of over 14.5%, surpassing USD 175.06 billion revenue by 2035.
North America advanced therapy medicinal products market is predicted to capture 44% share by 2035, driven by higher cases of cancer and neurological disorders and private investment.
Key players in the market include Novartis AG, Takeda Pharmaceutical Company Limited, Gilead Sciences, Inc., Bluebird Bio, Inc., BioMarin Pharmaceuticals Inc., Vericel Corporation, Mallinckrodt Pharmaceuticals, UniQure N.V., JCR Pharmaceuticals Co., Ltd., Spark Therapeutics, Inc., Kolon TissueGene, Inc.
